CONCORD NEWS IN YOUR INBOX: SIGN UP HERE

Recent Quotes
My Watchlist
Indicators
New Hampshire Stocks
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Greenwich LifeSciences, Inc. - Common stock (NQ:GLSI)

27.85 +1.11 (+4.15%)
Streaming Delayed Price Updated: 10:54 AM EDT, Mar 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Greenwich LifeSciences, Inc. - Common stock

< Previous 1 2 3 4 Next >
News headline image
69 Biggest Movers From Yesterday ↗
Gainers Powerbridge Technologies Co., Ltd. (NASDAQ: PBTS) shares climbed 189.9% to close at $1.12 on Thursday. 
Via Benzinga
News headline image
Greenwich LifeSciences to Resume Stock Repurchase Program
From Greenwich LifeSciences, Inc.
Via Business Wire
News headline image
Stocks That Hit 52-Week Lows On Wednesday ↗
On Wednesday, 73 stocks hit new 52-week lows. 
Via Benzinga
News headline image
Greenwich LifeSciences Provides Updates on Upcoming Phase III Clinical Trial & ASCO Meeting
From Greenwich LifeSciences, Inc.
Via Business Wire
News headline image
Greenwich LifeSciences to Participate in Upcoming Jefferies, Wainwright, ASCO and BIO International Conferences
From Greenwich LifeSciences, Inc.
Via Business Wire
News headline image
Greenwich LifeSciences Presents Phase IIb Data, Published at AACR 2022, Further Supporting the Role of GP2 in Preventing Metastatic Breast Cancer
From Greenwich LifeSciences, Inc.
Via Business Wire
News headline image
Recession Fears are Creating a Golden Opportunity for Biotech Stocks ↗
Biotech stocks are hard for novice investors to successfully profit from, but it's worth your time to learn the techniques now. 
Via InvestorPlace
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
Gainers Greenwich LifeSciences (NASDAQ:GLSI) stock moved upwards by 9.6% to $23.84 during Wednesday's after-market session. The market value of their outstanding shares is at $312.8 million. As per the... 
Via Benzinga
News headline image
78 Biggest Movers From Friday ↗
Gainers Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) surged 26% to close at $2.24. Y-mAbs reported completion of pre-BLA meeting with the FDA for Omburtamab. China Online Education... 
Via Benzinga
News headline image
Greenwich LifeSciences to Present at 2022 BIO CEO & Investor Conference
From Greenwich LifeSciences, Inc.
Via Business Wire
News headline image
62 Biggest Movers From Yesterday ↗
Gainers American Rebel Holdings, Inc. (NASDAQ: AREB) shares jumped 42.8% to close at $3.07 on Thursday following the company's recent uplisting to the Nasdaq.... 
Via Benzinga
News headline image
Greenwich LifeSciences Provides Update on Upcoming Phase III Clinical Trial, FLAMINGO-01
From Greenwich LifeSciences, Inc.
Via Business Wire
News headline image
3 Stocks Insiders Are Buying on Market Turbulence ↗
When insiders buy a stock, you should take it as a sign that they think good news is about to come out. Here are three to watch closely. 
Via InvestorPlace
News headline image
65 Biggest Movers From Yesterday ↗
Gainers Exterran Corporation (NYSE: EXTN) shares surged 59.7% to close at $4.79 on Monday after the company said it would merge with Enerflex to create a premier integrated... 
Via Benzinga
News headline image
Greenwich LifeSciences to Implement Stock Repurchase Program for up to $10 Million & to Extend Lock-up of Insiders for an Additional 1 Year
From Greenwich LifeSciences, Inc.
Via Business Wire
News headline image
Greenwich LifeSciences CEO Participates in TD Ameritrade Interview to Discuss 2021 SABCS Poster
From Greenwich LifeSciences, Inc.
Via Business Wire
News headline image
Greenwich LifeSciences Reveals 5-Year Data for GP2 Immunotherapy In Breast Cancer Settings ↗
Greenwich LifeSciences Inc (NASDAQ: GLSI) has published new GP2 Phase 2b trial data. The trial enrolled HER2 positive patients, who received a standard course of... 
Via Benzinga
News headline image
Greenwich LifeSciences Announces Presentation of 5 Year Data for GP2 Phase IIb Clinical Trial, Revealing Potential For New T Cell Platform Technology
From Greenwich LifeSciences, Inc.
Via Business Wire
News headline image
Greenwich LifeSciences to Participate in Multiple Interviews and Conferences
From Greenwich LifeSciences, Inc.
Via Business Wire
News headline image
Greenwich LifeSciences Expands Role of Industry Expert Dr. F. Joseph Daugherty to Include Medical Monitor for its Upcoming Phase III Clinical Trial
From Greenwich LifeSciences, Inc.
Via Business Wire
News headline image
Greenwich LifeSciences Announces Commencement of the First Commercial Line Filling of GP2
From Greenwich LifeSciences, Inc.
Via Business Wire
News headline image
Greenwich LifeSciences CEO Interview to Air on Bloomberg U.S. on the RedChip Money Report
From Greenwich LifeSciences, Inc.
Via Business Wire
News headline image
58 Biggest Movers From Friday ↗
Gainers Hagerty, Inc. (NYSE: HGTY) shares jumped 46.5% to close at $15.62. TuanChe Limited (NASDAQ: TC) gained 44.7% to settle at $3.30. IO Biotech, Inc. (NASDAQ: IOBT) shares... 
Via Benzinga
News headline image
Greenwich LifeSciences to Participate in Jefferies’ 12th Annual London Healthcare Conference
From Greenwich LifeSciences, Inc.
Via Business Wire
News headline image
Greenwich LifeSciences Announces Acceptance of Two Posters at Upcoming 2021 SABCS Breast Cancer Conference
From Greenwich LifeSciences, Inc.
Via Business Wire
News headline image
Greenwich LifeSciences Provides Clinical Update on Upcoming Phase III Clinical Trial, FLAMINGO-01
From Greenwich LifeSciences, Inc.
Via Business Wire
News headline image
Greenwich LifeSciences Provides Updated Corporate Presentation and Webcasts
From Greenwich LifeSciences, Inc.
Via Business Wire
News headline image
The Moonshot Investor: The Insider Track Strategy ↗
Excerpts of this article were originally published on October 4 and 18, 2021, as part of Tom Yeung's Moonshot Investor series. Investors interested in 
Via InvestorPlace
News headline image
3 Stocks Insiders Are Snapping Up. Do They Know Something We Don’t? ↗
Insider trading is heavily regulated, but it still happens, and it's worth paying attention to big moves from insiders for potential profits. 
Via InvestorPlace
News headline image
Greenwich LifeSciences to Partner with Susan G. Komen Race for the Cure Houston
From Greenwich LifeSciences, Inc.
Via Business Wire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Gift this article